{
    "hands_on_practices": [
        {
            "introduction": "Modern management of cervical pre-cancer is shifting from reflexive, result-based algorithms to a more nuanced, personalized paradigm based on a patient's estimated risk of progression. This exercise provides a hands-on opportunity to engage with the quantitative foundation of this approach. By using a simplified log-odds model, which mirrors the statistical engines driving current ASCCP risk-based guidelines, you will practice integrating multiple clinical data points—current results, prior screening, and histology—to calculate an individual's 5-year risk of developing CIN3+ ().",
            "id": "4465396",
            "problem": "A 32-year-old nonpregnant, immunocompetent patient presents for follow-up cervical cancer screening. The current co-test shows Human Papillomavirus (HPV) high-risk non-$16/18$ positivity with cytology indicating Low-Grade Squamous Intraepithelial Lesion (LSIL). The prior screening 12 months ago showed HPV high-risk non-$16/18$ positivity with cytology Negative for Intraepithelial Lesion or Malignancy (NILM). A prior colposcopy and biopsy performed 36 months ago demonstrated Cervical Intraepithelial Neoplasia grade 1 (CIN 1) without treatment. There is no history of immunosuppression, pregnancy, or treatment for Cervical Intraepithelial Neoplasia grade 2 or worse (CIN2+).\n\nYou are provided a simplified American Society for Colposcopy and Cervical Pathology (ASCCP) risk modeling table for 5-year Cervical Intraepithelial Neoplasia grade 3 or worse (CIN3+) risk that uses a log-odds additive framework. In this framework, the 5-year risk $p$ is obtained by computing a total log-odds score $L$ and then applying the logistic transformation. The model involves:\n\n- A baseline intercept $b$.\n- A current result contribution $L_{\\text{current}}$.\n- A prior screen contribution $L_{\\text{prior}}$ (from the most recent screen within 1–3 years).\n- A prior colposcopy/histology contribution $L_{\\text{colpo}}$ (from within the past 5 years).\n\nUse the following coefficients (log-odds contributions) and intercept:\n\n- Baseline intercept: $b = -4.0$.\n- Current result $L_{\\text{current}}$:\n  - HPV high-risk non-$16/18$ with NILM: $-3.0$.\n  - HPV high-risk non-$16/18$ with Atypical Squamous Cells of Undetermined Significance (ASC-US): $-2.2$.\n  - HPV high-risk non-$16/18$ with LSIL: $-1.6$.\n- Prior screen $L_{\\text{prior}}$ (most recent within 1–3 years):\n  - Prior HPV high-risk non-$16/18$ with NILM: $+0.3$.\n  - Prior HPV negative with NILM: $-0.5$.\n  - Prior unknown combination: $0$.\n- Prior colposcopy/histology $L_{\\text{colpo}}$ (within past 5 years):\n  - Prior biopsy showing CIN 1: $+0.4$.\n  - Prior biopsy negative/normal: $-0.2$.\n  - Prior treated CIN2+: $+0.9$.\n\nThe total log-odds is the sum $L = b + L_{\\text{current}} + L_{\\text{prior}} + L_{\\text{colpo}}$, and the 5-year CIN3+ risk is the logistic transform $p = \\dfrac{1}{1 + \\exp(-L)}$.\n\nFor surveillance interval selection, use the following management action thresholds based on $p$:\n\n- If $p < 0.0015$, return to routine 5-year screening.\n- If $0.0015 \\leq p < 0.0055$, return in 3 years.\n- If $p \\geq 0.0055$, return in 1 year.\n\nTask: Compute the patient’s 5-year CIN3+ risk $p$ using the provided coefficients and the logistic transformation. Then, identify which surveillance interval threshold applies. Express the final risk estimate as a decimal fraction with no unit and round your answer to four significant figures.",
            "solution": "The problem statement is first subjected to a rigorous validation process.\n\n### Step 1: Extract Givens\nThe following data are extracted verbatim from the problem statement:\n- Patient description: A 32-year-old nonpregnant, immunocompetent patient.\n- Current screening result: Human Papillomavirus (HPV) high-risk non-$16/18$ positivity with cytology indicating Low-Grade Squamous Intraepithelial Lesion (LSIL).\n- Prior screening (12 months ago): HPV high-risk non-$16/18$ positivity with cytology Negative for Intraepithelial Lesion or Malignancy (NILM).\n- Prior colposcopy/histology (36 months ago): Cervical Intraepithelial Neoplasia grade 1 (CIN 1) without treatment.\n- History: No history of immunosuppression, pregnancy, or treatment for Cervical Intraepithelial Neoplasia grade 2 or worse (CIN2+).\n- Model framework: A log-odds additive model for 5-year Cervical Intraepithelial Neoplasia grade 3 or worse (CIN3+) risk, denoted by $p$.\n- Total log-odds equation: $L = b + L_{\\text{current}} + L_{\\text{prior}} + L_{\\text{colpo}}$.\n- Logistic transformation: $p = \\dfrac{1}{1 + \\exp(-L)}$.\n- Model coefficients (log-odds):\n    - Baseline intercept: $b = -4.0$.\n    - Current result $L_{\\text{current}}$:\n        - HPV high-risk non-$16/18$ with NILM: $-3.0$.\n        - HPV high-risk non-$16/18$ with Atypical Squamous Cells of Undetermined Significance (ASC-US): $-2.2$.\n        - HPV high-risk non-$16/18$ with LSIL: $-1.6$.\n    - Prior screen $L_{\\text{prior}}$ (most recent within 1–3 years):\n        - Prior HPV high-risk non-$16/18$ with NILM: $+0.3$.\n        - Prior HPV negative with NILM: $-0.5$.\n        - Prior unknown combination: $0$.\n    - Prior colposcopy/histology $L_{\\text{colpo}}$ (within past 5 years):\n        - Prior biopsy showing CIN 1: $+0.4$.\n        - Prior biopsy negative/normal: $-0.2$.\n        - Prior treated CIN2+: $+0.9$.\n- Management action thresholds based on $p$:\n    - If $p < 0.0015$, return to routine 5-year screening.\n    - If $0.0015 \\leq p < 0.0055$, return in 3 years.\n    - If $p \\geq 0.0055$, return in 1 year.\n- Task: Compute $p$, identify the surveillance interval, and round $p$ to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated for validity.\n- **Scientifically Grounded**: The problem is based on a simplified version of the real-world risk-based management guidelines from the American Society for Colposcopy and Cervical Pathology (ASCCP). The use of a logistic regression (log-odds) model is a standard and scientifically sound method in epidemiology and clinical risk prediction. All terminology is used correctly. The problem is directly related to the medical topic of managing cervical intraepithelial neoplasia.\n- **Well-Posed**: The problem provides a complete set of patient data, a fully specified mathematical model, and all necessary parameters (coefficients and intercept). The tasks are clearly defined, leading to a unique, stable, and meaningful solution.\n- **Objective**: The problem is stated in precise, quantitative, and unbiased language, presenting a clinical scenario and a calculation task without any subjective elements.\n- **Consistency and Completeness**: The patient's history maps directly and unambiguously to the provided coefficient table. The timelines for prior results (12 months and 36 months) fall within the specified ranges (1–3 years and within 5 years, respectively). There are no missing or contradictory data.\n\n### Step 3: Verdict and Action\nThe problem is scientifically grounded, well-posed, objective, and self-contained. It is deemed **valid**. A solution will be derived.\n\n### Solution Derivation\nThe objective is to calculate the patient's 5-year risk of CIN3+, denoted as $p$, and to determine the corresponding management action. This is achieved by first calculating the total log-odds score, $L$, and then applying the logistic transformation.\n\n1.  **Identify Log-Odds Contributions:**\n    We map the patient's clinical history to the provided log-odds coefficients.\n    - The baseline intercept is given as $b = -4.0$.\n    - The current result is \"HPV high-risk non-$16/18$ with LSIL\". This corresponds to a contribution of $L_{\\text{current}} = -1.6$.\n    - The prior screening result at 12 months (which is within the 1–3 year window) was \"HPV high-risk non-$16/18$ with NILM\". This corresponds to a contribution of $L_{\\text{prior}} = +0.3$.\n    - The prior colposcopy/biopsy at 36 months (which is within the past 5 years) showed \"CIN 1\". This corresponds to a contribution of $L_{\\text{colpo}} = +0.4$.\n\n2.  **Calculate the Total Log-Odds Score ($L$):**\n    The total log-odds score is the sum of the individual contributions:\n    $$L = b + L_{\\text{current}} + L_{\\text{prior}} + L_{\\text{colpo}}$$\n    Substituting the identified values:\n    $$L = -4.0 + (-1.6) + 0.3 + 0.4$$\n    $$L = -5.6 + 0.7$$\n    $$L = -4.9$$\n\n3.  **Calculate the 5-Year CIN3+ Risk ($p$):**\n    The risk $p$ is calculated using the logistic transformation of $L$:\n    $$p = \\frac{1}{1 + \\exp(-L)}$$\n    Substituting the calculated value of $L = -4.9$:\n    $$p = \\frac{1}{1 + \\exp(-(-4.9))}$$\n    $$p = \\frac{1}{1 + \\exp(4.9)}$$\n    Now, we compute the numerical value:\n    $$\\exp(4.9) \\approx 134.2898$$\n    $$p \\approx \\frac{1}{1 + 134.2898} = \\frac{1}{135.2898}$$\n    $$p \\approx 0.00739150...$$\n    The problem requires the answer to be rounded to four significant figures. The first four significant figures are $7, 3, 9, 1$. The next digit is $5$, which requires rounding up the last significant figure.\n    $$p \\approx 0.007392$$\n\n4.  **Determine the Surveillance Interval:**\n    The final step is to compare the calculated risk $p$ with the management action thresholds.\n    - Thresholds:\n        - $p < 0.0015$ (5-year return)\n        - $0.0015 \\leq p < 0.0055$ (3-year return)\n        - $p \\geq 0.0055$ (1-year return)\n    - Our calculated risk is $p \\approx 0.007392$.\n    - We check the condition:\n    $$0.007392 \\geq 0.0055$$\n    This condition is true. Therefore, the applicable management action is to recommend the patient return in 1 year for surveillance.\n\nThe final risk estimate requested by the problem is the numerical value of $p$ rounded to four significant figures.",
            "answer": "$$\\boxed{0.007392}$$"
        },
        {
            "introduction": "Effective clinical practice frequently requires making critical decisions in the face of diagnostic uncertainty. This scenario presents a common and challenging dilemma: a high-risk cytology result (HSIL) coupled with an inadequate colposcopic evaluation, where the area most at risk for disease cannot be fully visualized. This exercise challenges you to synthesize foundational principles of colposcopy, risk stratification, and procedural safety to determine the most appropriate next step that resolves the diagnostic uncertainty while prioritizing patient safety ().",
            "id": "4465391",
            "problem": "A nonpregnant patient aged 30 years presents with a cervical cytology result of High-grade squamous intraepithelial lesion (HSIL). Human Papillomavirus (HPV) genotyping was not performed. Colposcopic evaluation reports that the Squamocolumnar Junction (SCJ) is not fully visualized and is therefore inadequate. Endocervical curettage (ECC) is performed and is negative for intraepithelial neoplasia. No exocervical biopsies reveal high-grade changes, although the examination is limited by partial visualization of the transformation zone.\n\nUsing the following fundamental base, determine the most appropriate next step in management:\n- Cervical intraepithelial neoplasia (CIN) arises from persistent infection with oncogenic Human Papillomavirus (HPV) types, and High-grade squamous intraepithelial lesion (HSIL) cytology correlates strongly with histologic CIN 2 or CIN 3.\n- The goal of colposcopic evaluation is to fully assess the transformation zone, identify and biopsy abnormal areas, visualize the SCJ, and sample the endocervical canal when indicated.\n- When the SCJ is not fully visualized, colposcopy is considered inadequate, and the absence of visible lesions does not exclude endocervical disease.\n- The sensitivity of ECC for detecting endocervical CIN2+ is imperfect; a single negative ECC does not sufficiently lower pretest probability when cytology predicts high-grade disease.\n- Risk-based management as per the American Society for Colposcopy and Cervical Pathology (ASCCP) applies immediate risk thresholds for CIN3+: expedited treatment is preferred when risk is $\\geq 60\\%$ and acceptable when risk is in the 25% to 60% range; HSIL cytology in nonpregnant patients aged $\\geq 25$ years generally meets at least the acceptable threshold.\n- Ablative modalities require complete visualization of the SCJ and transformation zone to ensure no endocervical disease is missed and are contraindicated when colposcopy is inadequate.\n\nWhich option best aligns with these principles to minimize the probability of missed high-grade disease while obtaining definitive diagnosis and margins?\n\nA. Offer expedited excisional management with a diagnostic Loop Electrosurgical Excision Procedure (LEEP), after counseling on risks and benefits, given HSIL cytology, inadequate colposcopy, and negative ECC.\n\nB. Continue surveillance with repeat cytology and HPV cotesting at 12 months because the ECC is negative.\n\nC. Perform ablative therapy (for example, cryotherapy) of the transformation zone since the ECC is negative and no high-grade lesions are seen.\n\nD. Defer intervention and repeat colposcopy with ECC in 6 weeks to improve visualization before considering treatment.\n\nE. Proceed directly to total hysterectomy because HSIL cytology indicates high risk for invasive cancer.",
            "solution": "**3. Problem Validation:**\n\n**Step 1: Extract Givens**\n- Patient: nonpregnant, aged 30 years.\n- Cervical cytology result: High-grade squamous intraepithelial lesion (HSIL).\n- Human Papillomavirus (HPV) genotyping: Not performed.\n- Colposcopic evaluation:\n    - Squamocolumnar Junction (SCJ) not fully visualized.\n    - Colposcopy is inadequate.\n    - No exocervical biopsies reveal high-grade changes.\n    - Examination is limited by partial visualization of the transformation zone.\n- Endocervical curettage (ECC): Negative for intraepithelial neoplasia.\n- Given \"Fundamental Base\" (Principles):\n    1. CIN arises from persistent oncogenic HPV. HSIL cytology correlates strongly with histologic CIN 2 or CIN 3.\n    2. Goal of colposcopy: fully assess transformation zone, biopsy abnormal areas, visualize SCJ, sample endocervical canal.\n    3. Inadequate colposcopy (SCJ not fully visualized) means absence of visible lesions doesn't exclude endocervical disease.\n    4. ECC has imperfect sensitivity for CIN2+. A single negative ECC is not sufficient to rule out high-grade disease when cytology is HSIL.\n    5. Risk-based management (ASCCP):\n        - Expedited treatment preferred if CIN3+ risk $\\geq 60\\%$.\n        - Expedited treatment acceptable if CIN3+ risk is 25% to 60%.\n        - HSIL cytology in nonpregnant patients aged $\\geq 25$ years meets at least the acceptable threshold.\n    6. Ablative modalities (e.g., cryotherapy) are contraindicated when colposcopy is inadequate because they require complete visualization of the SCJ to ensure no endocervical disease is missed.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded?** Yes. The problem statement and the provided principles are consistent with current medical knowledge and guidelines for the management of abnormal cervical cancer screening results, specifically from organizations like the ASCCP. The concepts of HSIL, CIN, colposcopy, ECC, LEEP, and risk-based management are all standard in gynecology.\n- **Well-Posed?** Yes. There is a clear clinical scenario and a set of principles to apply. The question asks for the \"most appropriate next step,\" which implies a single best answer among the options, derivable from the given principles.\n- **Objective?** Yes. The language is clinical, precise, and free of subjective or opinion-based statements. The patient data is specific.\n- **Flaws?** Let's check the list:\n    1. **Scientific/Factual Unsoundness:** No. The premises are sound.\n    2. **Non-Formalizable/Irrelevant:** No. This is a classic clinical management problem directly related to the field.\n    3. **Incomplete/Contradictory Setup:** The setup is complete and consistent. We have the patient's age, cytology, and colposcopy findings. The principles provide the framework for decision-making. There are no contradictions. The fact that HPV genotyping was not performed is a relevant piece of information that affects risk stratification but doesn't invalidate the problem; the principles provided allow a decision even without it.\n    4. **Unrealistic/Infeasible:** No. This scenario is a common clinical challenge.\n    5. **Ill-Posed/Poorly Structured:** No. The question is clear and a unique, best answer should be derivable.\n    6. **Pseudo-Profound/Trivial:** No. The problem requires careful application of multiple principles to navigate a situation with conflicting information (high-grade cytology vs. negative biopsies/ECC) and an inadequate diagnostic procedure. It's a genuine clinical reasoning problem.\n    7. **Outside Scientific Verifiability:** No. The management choices have outcomes that can be studied and verified.\n\n**Step 3: Verdict and Action**\n- **Verdict:** The problem is valid.\n- **Action:** Proceed to the solution phase.\n\n**4. Solution Derivation:**\n\nI need to synthesize the given information and principles to determine the best course of action.\n\n- **Patient Status:** Age 30, nonpregnant, HSIL cytology.\n- **Principle 1 & 5:** HSIL cytology implies a high probability of underlying CIN 2 or CIN 3. The immediate risk of CIN3+ is high enough to warrant consideration of expedited treatment (risk is in the 25% to 60% range, at least). The goal is to diagnose and treat this potential high-grade lesion.\n- **Diagnostic Findings:**\n    - Colposcopy: Inadequate. The SCJ and the full extent of any potential lesion are not seen. Biopsies of the visible ectocervix were negative for high-grade disease, but this is an incomplete assessment.\n    - ECC: Negative.\n- **Principle 3 & 4:** An inadequate colposcopy and a negative ECC are **insufficient** to rule out high-grade disease, especially in the endocervical canal, given the high pre-test probability from the HSIL cytology. The sensitivity of ECC is not perfect. Therefore, we cannot be reassured by the negative findings. A significant risk of occult high-grade disease (CIN2+) located in the endocervical canal or just beyond the visible portion of the transformation zone remains.\n- **Synthesizing the situation:** We have a high-risk patient (HSIL) with an inconclusive diagnostic workup (inadequate colposcopy, negative but potentially false-negative ECC). We cannot simply observe, nor can we perform a treatment that doesn't also provide a definitive tissue diagnosis of the unseen area.\n- **Principle 6:** Ablative therapies (like cryotherapy or laser ablation) are explicitly contraindicated. These treatments destroy the tissue without providing a specimen for histologic confirmation. If there's an unseen lesion in the canal, an ablative procedure would destroy it without confirming its grade and could mask an underlying invasive cancer. This is a critical safety principle.\n- **The Core Dilemma:** The patient has a high risk of CIN2+ based on cytology, but the diagnostic workup has failed to locate and histologically confirm it. The location of the potential lesion is unknown, but it is suspected to be within the endocervical canal or the unvisualized portion of the transformation zone.\n- **The Required Action:** The next step must achieve two goals simultaneously: (1) provide a definitive histologic diagnosis of the unvisualized area (the endocervical canal and the entire transformation zone) and (2) be therapeutic if high-grade disease is found. This points directly to an excisional procedure.\n- **Excisional Procedures:** A diagnostic excisional procedure, such as a Loop Electrosurgical Excision Procedure (LEEP) or a cold-knife conization, removes the entire transformation zone, including a portion of the endocervical canal. The removed tissue is then sent for histopathology. This accomplishes both goals: it provides a definitive diagnosis by sampling the at-risk area that was not visualized, and it is often therapeutic, as it removes the lesion.\n\nNow I will evaluate each option based on this derivation.\n\n**Option A: Offer expedited excisional management with a diagnostic Loop Electrosurgical Excision Procedure (LEEP), after counseling on risks and benefits, given HSIL cytology, inadequate colposcopy, and negative ECC.**\n- **Evaluation:** This aligns perfectly with the reasoning. The patient has a high-risk cytology (HSIL). The colposcopy was inadequate, meaning a lesion could be hidden in the endocervical canal. The negative ECC is not reassuring due to its imperfect sensitivity (Principle 4). An excisional procedure like LEEP is both diagnostic (provides a tissue specimen of the entire transformation zone and distal endocervical canal) and therapeutic. This is the standard of care in this \"see-and-treat\" or, more accurately, \"diagnose-and-treat\" scenario. It directly addresses the problem of the unvisualized SCJ and the high pre-test probability of disease. It adheres to the risk-based management principle (Principle 5) by offering expedited treatment/diagnosis.\n- **Verdict:** Correct.\n\n**Option B: Continue surveillance with repeat cytology and HPV cotesting at 12 months because the ECC is negative.**\n- **Evaluation:** This would be \"watchful waiting.\" Given the high-risk HSIL cytology, waiting 12 months is inappropriate. The negative ECC is not sufficient to downgrade the risk to a level where surveillance is safe (Principle 4). The risk of having or developing CIN3+ is high (Principle 5), and delaying diagnosis/treatment for a year could allow a high-grade lesion or even an occult cancer to progress. This would be a significant departure from standard care.\n- **Verdict:** Incorrect.\n\n**Option C: Perform ablative therapy (for example, cryotherapy) of the transformation zone since the ECC is negative and no high-grade lesions are seen.**\n- **Evaluation:** This is explicitly contraindicated by Principle 6. Ablative therapies are only appropriate when colposcopy is adequate (SCJ fully visualized) and there is no evidence of endocervical glandular disease. Since the colposcopy was inadequate, there is a risk of an unseen lesion in the endocervical canal. Ablating the ectocervix would not treat this potential lesion and could cause the new SCJ to retract further into the canal, making future surveillance even more difficult. It also fails to provide a tissue diagnosis.\n- **Verdict:** Incorrect.\n\n**Option D: Defer intervention and repeat colposcopy with ECC in 6 weeks to improve visualization before considering treatment.**\n- **Evaluation:** While repeating a colposcopy can sometimes be useful if factors like inflammation or infection were thought to obscure visualization, the problem statement does not suggest this. The reason for an inadequate colposcopy is often anatomical (e.g., in postmenopausal women or after prior procedures), and it's unlikely to change in 6 weeks for a 30-year-old. More importantly, this approach delays definitive management for a high-risk condition (HSIL) without a strong rationale for why the repeat procedure would be more successful. Given the high risk, and the availability of a definitive diagnostic-therapeutic procedure (LEEP), another attempt at a potentially inconclusive procedure is a less optimal strategy. The risk of CIN3+ is high enough to proceed to a more definitive step.\n- **Verdict:** Incorrect.\n\n**Option E: Proceed directly to total hysterectomy because HSIL cytology indicates high risk for invasive cancer.**\n- **Evaluation:** This is overtly aggressive and inappropriate. A hysterectomy is a major surgery with significant morbidity. It is a treatment for invasive cervical cancer or, in some very specific cases, for persistent, recurrent high-grade dysplasia after less invasive treatments have failed, especially in a patient who has completed childbearing. For a 30-year-old patient with HSIL cytology but no biopsy-proven cancer, proceeding directly to hysterectomy is a drastic overtreatment. The first step is always to obtain a histologic diagnosis via excisional biopsy (like LEEP or cone biopsy). HSIL is a precursor to cancer, not cancer itself. A hysterectomy is not a primary diagnostic tool for CIN.\n- an important point is that without confirming a CIS or invasive cancer, hysterectomy for CIN is generally not the first-line treatment. LEEP is diagnostic and therapeutic. Hysterectomy is only therapeutic, and you would be doing it without a tissue diagnosis of the extent of disease.\n- **Verdict:** Incorrect.\n\n**Conclusion:**\nThe logic flows from:\n- High-risk cytology (HSIL).\n- Inadequate diagnostic workup (colposcopy not visualizing SCJ).\n- Unreliability of negative ECC in this context.\n- Therefore, a procedure that is both diagnostic for the unvisualized area and therapeutic is required.\n- This procedure is an excisional one (LEEP or cone biopsy).\n- Ablation is contraindicated.\n- Surveillance is too risky.\n- Hysterectomy is overtreatment.\n\nThus, option A is the only one that correctly applies all the provided principles.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Clinical management guidelines must balance the benefits of treatment for individuals against the potential for harm and resource use at a population level. This practice shifts the perspective from the individual patient to a public health program, examining the trade-offs between different management strategies for HSIL cytology. Using the fundamental concept of positive predictive value (PPV), you will quantify the public health challenge of overtreatment in a \"see-and-treat\" model and compare it to a \"confirmatory biopsy\" model, providing a tangible understanding of how different clinical pathways impact a population of patients ().",
            "id": "4571391",
            "problem": "A public health program is evaluating two management strategies for individuals with high-grade squamous intraepithelial lesion (HSIL) cytology in a cervical cancer screening pathway. The target disease threshold for treatment is cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Assume the following foundational definitions and facts:\n\n- The positive predictive value (PPV) is defined as the probability that an individual has the target disease given a positive screening test, that is, $\\Pr(\\text{CIN}2+ \\mid \\text{HSIL})$.\n- In a cohort of HSIL cytology patients, the number with CIN2+ is the product of the cohort size and the PPV, and the number without CIN2+ is the cohort size minus the number with CIN2+.\n- In a see-and-treat strategy, all individuals with HSIL cytology are treated immediately without confirmatory histology. Overtreatment is defined as treatment delivered to individuals who do not have CIN2+.\n- In a two-visit confirmatory strategy, individuals with HSIL cytology are asked to return for a diagnostic biopsy. Only those with biopsy-confirmed CIN2+ are treated. Assume biopsy is a perfect reference standard (no misclassification). A fraction $L$ of individuals are lost to follow-up (LTFU) between cytology and biopsy and therefore receive no treatment. Individuals who do not have CIN2+ are not treated.\n- Treat all instances as independent and assume the PPV applies uniformly across the cohort.\n\nSuppose the PPV of HSIL cytology for CIN2+ is $0.65$. Consider a cohort of $500$ individuals with HSIL cytology. In the two-visit model, the loss to follow-up fraction is $L = 0.20$. Using only the definitions above, compute the absolute reduction in the number of overtreated individuals when switching from the see-and-treat policy to the two-visit confirmatory biopsy model. Provide your final answer as a single number representing the count of individuals. Do not use a percentage sign anywhere. If rounding is required, round to four significant figures; otherwise, provide the exact value.",
            "solution": "We begin from the definition of positive predictive value (PPV). For a cohort of size $N$ with a positive screening test, the expected number with the target disease is $N \\times \\text{PPV}$, and the expected number without the target disease is $N - N \\times \\text{PPV} = N \\times (1 - \\text{PPV})$.\n\nLet $N = 500$, and let the positive predictive value be $\\text{PPV} = 0.65$. Then:\n- The expected number with CIN2+ is\n$$\nN_{\\text{disease}} = N \\times \\text{PPV} = 500 \\times 0.65 = 325.\n$$\n- The expected number without CIN2+ is\n$$\nN_{\\text{no disease}} = N \\times (1 - \\text{PPV}) = 500 \\times (1 - 0.65) = 500 \\times 0.35 = 175.\n$$\n\nUnder the see-and-treat strategy, every individual with HSIL cytology is treated immediately. By the definition of overtreatment (treatment in the absence of CIN2+), the number overtreated is exactly the number without CIN2+:\n$$\n\\text{Overtreated}_{\\text{see-and-treat}} = N_{\\text{no disease}} = 175.\n$$\n\nUnder the two-visit confirmatory biopsy model, individuals are asked to return for biopsy, with a loss to follow-up fraction $L = 0.20$. Only biopsy-confirmed CIN2+ cases are treated, and biopsy is assumed to be a perfect reference standard (no false positives and no false negatives). Individuals without CIN2+ are not treated regardless of whether they return, and those lost to follow-up receive no treatment. Therefore, by definition, there is no treatment given to individuals without CIN2+ in this model:\n$$\n\\text{Overtreated}_{\\text{two-visit}} = 0.\n$$\n\nThe absolute reduction in the number of overtreated individuals when switching from see-and-treat to the two-visit model is the difference:\n$$\n\\Delta = \\text{Overtreated}_{\\text{see-and-treat}} - \\text{Overtreated}_{\\text{two-visit}} = 175 - 0 = 175.\n$$\n\nThis result does not require rounding, as it is an exact integer count derived from the given parameters and definitions.",
            "answer": "$$\\boxed{175}$$"
        }
    ]
}